Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Delcath Systems Inc DCTH

Healthcare Medical Devices Diagnostics & Research
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT) percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while... see more

Recent & Breaking News (NDAQ:DCTH)

Delcath Adds New U.S. Center To Global Phase 2 Hepatocellular Carcinoma Program

PR Newswire April 7, 2015

Delcath Activates Prospective Registry In Europe

PR Newswire April 2, 2015

Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting

PR Newswire March 27, 2015

Delcath Reports 2014 Fourth Quarter And Full Year Financial Results

PR Newswire March 10, 2015

Delcath Announces Melphalan/HDS Poster Presentation To Be Presented At The Society Of Surgical Oncology Annual Meeting

PR Newswire March 9, 2015

Delcath Announces Submission Of Phase 3 Trial Results For Publication In A Leading Peer-Reviewed Medical Journal

PR Newswire March 3, 2015

Delcath To Present At The 27th Annual Roth Conference

PR Newswire March 2, 2015

Delcath Prices $2.8 Million Public Offering of Common Stock and Warrants

PR Newswire February 11, 2015

Delcath Announces Proposed Public Offering Of Common Stock And Warrants

PR Newswire February 10, 2015

DELCATH RECEIVES VALUE 4 REIMBUREMENT STATUS FOR CHEMOSAT IN GERMANY

Thomson Reuters ONE February 3, 2015

DELCATH STRENGTHENS BOARD OF DIRECTORS WITH NEW APPOINTMENTS

Thomson Reuters ONE December 15, 2014

DELCATH ADDS NEW CENTERS TO GLOBAL PHASE 2 HCC PROGRAM

Thomson Reuters ONE December 11, 2014

DELCATH ANNOUNCES TREATMENT OF FIRST PATIENT IN PHASE 2 TRIAL OF MELPHALAN HEPATIC DELIVERY SYSTEM IN PRIMARY LIVER CANCER

Thomson Reuters ONE November 10, 2014

Delcath Reports 2014 Third Quarter Results

PR Newswire November 5, 2014

DELCATH TO REPORT THIRD QUARTER 2014 RESULTS ON NOVEMBER 5, 2014

Thomson Reuters ONE October 29, 2014

LEADING CANCER CENTERS TO PRESENT DATA FROM DELCATH'S CHEMOSAT/MELPHALAN HDS AT ESSO CONGRESS

Thomson Reuters ONE October 28, 2014

DELCATH COMMENCES U.S. PHASE 2 STUDY OF MELPHALAN HEPATIC DELIVERY SYSTEM IN PRIMARY LIVER CANCER

Thomson Reuters ONE October 2, 2014

Jennifer Simpson, PH. D. Appointed Interim President and Interim-CEO of Delcath Systems; Roger G. Stoll, PH.D Named Executive Chairman

Thomson Reuters ONE September 15, 2014

Delcath Reports 2014 Second Quarter Results

PR Newswire August 6, 2014

DELCATH TO REPORT SECOND QUARTER 2014 RESULTS ON AUGUST 6, 2014

Thomson Reuters ONE August 1, 2014